Delirium Treatment Drugs Market Segmentation:
By Drug Class
- Antipsychotics
- Anesthetics
- Anticonvulsants
- Antidepressants
- Sedative Hypnotics
- Cholinesterase inhibitors
By Diagnosis
- Subsyndromal delirium
- Delirium tremens
- Hypoactive delirium
- Hyperactive delirium
- Mixed delirium
- Others
By End User
- Hospitals
- Clinics
- Homecare
- Others (rehab centers, LTC facilities etc.)
By Route of Administration
- Oral
- Intravenous
- Intramuscular
- Others (sublingual, transdermal etc.)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The current market size is USD 2.8 billion in 2023.
Increasing geriatric population, rising prevalence of target indication, investments in product development.
Safety issues with antipsychotics, misdiagnosis of delirium patients, lack of approved pharmacological interventions.
Antipsychotic drugs are the leading segment with over 40% market share.
Pfizer, Johnson & Johnson, Eli Lilly, AstraZeneca, Novartis etc.
The market is expected to grow at 5.9% CAGR, reaching USD 4.4 billion by 2031.
Increasing geriatric population, rising prevalence of dementia and Alzheimer's disease, growing awareness about delirium management.